| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
Rat calcitonin gene-related peptide II (CGRP II) TFA can induce vasodilation in the small-diameter left anterior descending artery (LAD) of pigs, with an EC50 value of 0.56 nM[1]. Rat CGRP II TFA can relax the spontaneous tension of the isolated anal sphincter (IAS) band, with an EC50 value of 83 μM[2]. Rat CGRP II TFA (rβCGRP) can inhibit the binding of [125I]hαCGRP (IC50: 7 nM) and stimulate the accumulation of cAMP in cells co-expressing mRAMP1 (mouse receptor activity regulator 1) and rCRLR (rat calcitonin receptor-like receptor) (EC50: 0.56 nM)[3]. Calcitonin gene-related peptide II rat TFA (rat-βCGRP, 0.01-100 nM) can induce coronary artery endothelial dysplasia in male and female Sprague-Dawley rats with an IC50 value of approximately 2.8 nM[4].
|
|---|---|
| ln Vivo |
Calcitonin gene-related peptide II rat TFA (rat-βCGRP, single injection, 0.3 μg/kg, 10-minute interval) can induce hypotension and vasodilation in male Sprague-Dawley rats[5].
|
| Animal Protocol |
Animal/Disease Models:Male Sprague-Dawley rats [5]
Doses: 0.01 ng/kg - 3 μg/kg (100 μL), followed by flushing with 150 μL of isotonic saline every 10 minutes.< Route of Administration: Single injection Experimental Results: Induced dilation of the pial arteries (PA) and increased local cortical cerebral blood flow (LCBFFlux). |
| References |
|
| Molecular Formula |
C163H267N51O50S2.XC2HF3O2
|
|---|---|
| Molecular Weight |
3805.31 (free base)
|
| Related CAS # |
Calcitonin Gene Related Peptide II (rat)
|
| Sequence |
Ser-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (Disulfide bridge: Cys2-Cys7)SCNTATCVTHRLAGLLSRSGGVVKDNFVPTNVGSKAF-NH2 (Disulfide bridge: Cys2-Cys7)
|
| SequenceShortening |
SCNTATCVTHRLAGLLSRSGGVVKDNFVPTNVGSKAF-NH2 (Disulfide bridge: Cys2-Cys7)
|
| Appearance |
White to off-white solid
|
| Synonyms |
CGRP II (rat) TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
